Authors: František Neuwirth, Vlaďka Laštůvková
On 14 June 2023, the Czech government approved an amendment to the Act on Medicines, which imposes new obligations on marketing authorisation holders (“MAH”), distributors and pharmacies in order to ensure the availability of medicinal products on the Czech market. The proposal will now be debated in the Chamber of Deputies.
In order to achieve the above objective, the amendment proposes to introduce three sets of measures:
It is also proposed to abolish the current protected distribution system (known as “Lex Pawlas”), i.e. (in short) the obligation of the MAH to supply to a distributor who has made a written declaration to the MAH that it requires the medicinal product for patient care in the Czech Republic.
According to its current wording, the proposal should enter into force on the first day of the month following its publication in the Collection of Laws. Taking into account the standard length of the legislative process, it can be estimated that the proposal could enter into force on 1 November 2023 or 1 December 2023. However, it is proposed to postpone the applicability of certain obligations by several months (see below).
* No draft of this decree is available yet. According to a publicly available outline of this decree, the proposed exemption could apply, for example, to advanced therapy medicinal products, seasonal vaccines, short-expiring medicinal products, radionuclide generators and radionuclide precursors.
HOW IS THE PARLIAMENTARY DEBATE GOING TO CHANGE THE PROPOSAL?
The table above summarises the proposal as approved by the government. The approved wording differs from the original proposal of the Ministry of Health mainly in details and technicalities, despite the large number of comments made during the comment procedure. It remains to be seen whether and how the proposal will be amended during the parliamentary debate.